LMOD3-Associated Nemaline Myopathy: Prenatal Ultrasonographic, Pathologic, and Molecular Findings.
Michal BerkenstadtBen Pode-ShakkedOrtal BarelHila BarashReuven AchironYinon GilboaDvora KidronAnnick Raas-RothschildPublished in: Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine (2018)
To describe the prenatal presentation, including ultrasonographic, histologic, and molecular findings, in 2 fetuses affected with LMOD3-related nemaline myopathy. Prenatal ultrasonographic examinations and histopathologic studies were performed on 2 fetuses with evidence of nemaline myopathy. To establish a molecular diagnosis, whole-exome sequencing was pursued for the affected fetuses. Nemaline myopathy is a common form of congenital myopathy manifesting with nonprogressive generalized muscle weakness, hypotonia, and electron-dense protein inclusions in skeletal myofibers. Although clinically, nemaline myopathy can be viewed as a common pathway phenotype, its molecular basis is heterogeneous, with mutations in 11 identified genes implicated in its pathogenesis so far. Whole-exome sequencing revealed that the affected fetuses were compound heterozygous for 2 newly reported pathogenic variants in the LMOD3 gene, which encodes leiomodin 3. To our knowledge, this article is the first report of LMOD3-related nemaline myopathy since the original reported cohort. We provide a detailed description of the prenatal imaging of these affected fetuses, which we hope, in combination with next-generation sequencing, may contribute to further diagnosis in additional families.
Keyphrases
- late onset
- gestational age
- muscular dystrophy
- pregnant women
- early onset
- copy number
- genome wide
- healthcare
- high resolution
- neoadjuvant chemotherapy
- squamous cell carcinoma
- dna methylation
- optic nerve
- lymph node
- genome wide identification
- mass spectrometry
- locally advanced
- drug induced
- duchenne muscular dystrophy
- optical coherence tomography
- protein protein
- radiation therapy
- genome wide analysis
- circulating tumor cells
- case control